tirzepatide medication Semaglutide vs for Weight Loss New Tirzepatide Access and Pricing

Embla coaches work with members to: Set achievable goals and build consistency in daily behaviors Identify and defuse unhelpful thoughts and food-related coping patterns Prepare for plateaus and relapses and navigate through them Develop the confidence and skills to maintain weight loss for life Real-world outcomes: what employers should expect Employers implementing coaching-first models like Embla's can expect: Improved medication efficiency members use lower doses and taper sooner, which reduces total drug spend Higher engagement and adherence weekly video coaching drives strong retention and satisfaction Lower long-term costs less reliance on high-cost GLP-1s, fewer comorbidities, and healthier employee populations Transparent reporting dashboards that track individual and population-level outcomes, including weight loss, medication usage, and program ROI We've worked with employers where 8085% of members stay engaged for 6+ months, and more than half continue engaging after medication has ended because they've built a trusted relationship with their coach

Thats because Wegovy is the only one of the two that is officially licensed in the UK for weight management

One large observational study of 461,382 patients taking GLP-1 medications found that 15.1% developed vitamin deficiencies over 12 months, including 13.6% with vitamin D deficiency, 0.0% with niacin deficiency, and 0.1% with thiamine deficiency

Doses of semaglutide ranging from 0.1-1.6 mg resulted in a 2.1%, 7.0%, 13.0%, 37.5%, 51.2%, and 63.6% respective dose-dependent increases in the proportion of patients that achieved a 5%, or greater, reduction in weight loss